Cargando…
First person – Mugagga Kalyesubula and Ramgopal Mopuri
First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 thera...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988767/ http://dx.doi.org/10.1242/dmm.048941 |
_version_ | 1783668843467505664 |
---|---|
collection | PubMed |
description | First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition’, published in DMM. Mugagga is a PhD student in the lab of Dr Hay Dvir at the Volcani Center – Agricultural Research Organization (ARO), Rishon LeZion, Israel and The Hebrew University of Jerusalem, Rehovot, Israel, investigating therapy development for chronic metabolic diseases such as non-alcoholic fatty liver disease. Ramgopal is a postdoctoral researcher in the lab of Dr Hay Dvir at the Volcani Center – ARO in Rishon LeZion, Israel, developing therapeutic approaches for the management of fatty liver diseases. |
format | Online Article Text |
id | pubmed-7988767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-79887672021-03-25 First person – Mugagga Kalyesubula and Ramgopal Mopuri Dis Model Mech First Person First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition’, published in DMM. Mugagga is a PhD student in the lab of Dr Hay Dvir at the Volcani Center – Agricultural Research Organization (ARO), Rishon LeZion, Israel and The Hebrew University of Jerusalem, Rehovot, Israel, investigating therapy development for chronic metabolic diseases such as non-alcoholic fatty liver disease. Ramgopal is a postdoctoral researcher in the lab of Dr Hay Dvir at the Volcani Center – ARO in Rishon LeZion, Israel, developing therapeutic approaches for the management of fatty liver diseases. The Company of Biologists Ltd 2021-03-18 /pmc/articles/PMC7988767/ http://dx.doi.org/10.1242/dmm.048941 Text en © 2021. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | First Person First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title | First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title_full | First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title_fullStr | First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title_full_unstemmed | First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title_short | First person – Mugagga Kalyesubula and Ramgopal Mopuri |
title_sort | first person – mugagga kalyesubula and ramgopal mopuri |
topic | First Person |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988767/ http://dx.doi.org/10.1242/dmm.048941 |